Last reviewed · How we verify
NCT04840134
From Hardship to Hope: A Peer-led Intervention to Reduce Financial Hardship and Suicide Risk
NA trial testing From Hardship to Hope: A Peer-led intervention to reduce financial hardship and suicide risk in Suicide in 96 participants. Suspended.
30 March 2027
Quick facts
| Lead sponsor | New York State Psychiatric Institute |
|---|---|
| Phase | NA |
| Status | Suspended |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 96 |
| Start date | 8 June 2021 |
| Primary completion | 30 March 2027 |
| Estimated completion | 30 March 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- From Hardship to Hope: A Peer-led intervention to reduce financial hardship and suicide risk
- Enhanced Treatment as Usual (eTAU)
Conditions studied
- Suicide — all drugs for Suicide →
- Suicide Ideation — all drugs for Suicide Ideation →
- Suicidal Behavior — all drugs for Suicidal Behavior →
- Hope — all drugs for Hope →
Sponsor
New York State Psychiatric Institute
Who can join
Adults 18 to 64, any sex, with Suicide or Suicide Ideation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Financial hardship is an important risk factor for suicide. However, there are no evidence-based interventions to help individuals at risk for suicide to improve their financial situation. The intervention will support participants to address their financial difficulties (e.g., indebtedness, inability to meet basic needs) by coaching them to develop key financial management skills (e.g., budgeting, debt management), create a financial wellness action plan, map and activate their social networks, and connecting them with community-based financial supports (e.g., free financial counseling, publicly funded housing and food supports). The intervention will be facilitated by trained peer coaches. The intervention will consist of three phases: (1) intensive; (2) intermediate; and (3) follow-up. The 6-week intensive phase will consist of 6 weekly group sessions and 4 one-on-one coaching sessions to navigate financial resources. The intermediate phase will consist of 3 biweekly group sessions, and either 3 biweekly or 2 monthly one-on-one coaching sessions, based on participant preference. The follow-up phase will offer 3 monthly group sessions, and either 3 monthly or 6 biweekly one-on-one coaching sessions based on participant preference. Group and one-on-one coaching sessions will be conducted remotely via a HIPAA-compliant videoconferencing platform. This study will consist of five steps: (1) obtaining input from stakeholders to develop the intervention; (2) piloting it with a small sample of participants (n=10); (3) using this information to revise the intervention; (4) testing it in a randomized controlled trial with individuals experiencing financial hardship and suicide risk (n=96); and (5) finalizing the intervention manual.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04840134
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Suicide
Currently open trials in the same condition.
- NCT07404787 — Evaluation of a Telehealth Case Management Intervention to Prevent Suicide Among Soldiers Discharged From Psychiatric Ho · NA · recruiting
- NCT07214233 — Youth Empowerment and Safety Intervention · NA · recruiting
- NCT07343258 — Pilot Study on Follow-Up of (Acutely) Suicidal Individuals From the Flemish Suicide Helpline · NA · recruiting
- NCT07523490 — Investigation on Suicide Risk Factors of Patients With Mood Disorders · recruiting
- NCT06571916 — Brief Skills for Safer Living (Brief-SfSL) · NA · recruiting
Other New York State Psychiatric Institute trials
Trials by the same sponsor.
- NCT05416658 — Shared Decision Making for Antipsychotic Medications · NA · not yet recruiting
- NCT07423546 — A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia · Phase 1, PHASE2 · not yet recruiting
- NCT05339256 — Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual · Phase 2 · not yet recruiting
- NCT05563948 — Repeated Administration of Cannabis Varying in THC and CBD · Phase 2 · suspended
- NCT06977308 — A Multimodal Imaging Study of Dopamine in Early Psychosis · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04840134 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New York State Psychiatric Institute
- Last refreshed: 6 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04840134.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing